Sanofi
Sanofi’s Dupixent shows strength at Phase 3 in eosinophilic esophagitis
October 27, 2020Manufacturing and Production Dupixent, Sanofi, pharma
Sanofi has lifted the curtain on new Phase 3 data for Dupixent (dupilumab), showing that the drug met all of …
Sanofi’s Dupixent chalks up CHMP recommendation for paediatric severe atopic dermatitis
October 19, 2020Sales and Marketing Dupixent, EMA, Sanofi, atopic dermatitis
Sanofi’s interleukin-4 and -13 inhibitor Dupixent (dupilumab) has been given the recommendation of the European Medicines Agency’s Committee for Medicinal …
NICE approves Sanofi’s Sarclisa combo for relapsed/refractory multiple myeloma
October 16, 2020Medical Communications, Sales and Marketing NICE, Sanofi, Sarclisa, multiple myeloma
Sanofi’s Sarclisa (isatuximab) has secured a recommendation from NICE for routine use on the NHS in England and Wales as …
Promising Phase 2 data for Sanofi and Regeneron’s PD-1 inhibitor Libtayo in locally advanced basal cell carcinoma
September 18, 2020Medical Communications, Research and Development Cancer, ESMO 2020, Libtayo, Regeneron, Sanofi, pharma
Promising Phase 2 data has been released at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 for Sanofi …
Extension study reveals Dupixent’s benefit can last up to three years in moderate-to-severe asthma
September 8, 2020Manufacturing and Production, Research and Development Dupixent, Sanofi, asthma, pharma
New findings have been revealed from an extension study of Sanofi’s interleukin-4 (IL-4) and interleukin-13 (IL-13) inhibitor Dupixent (dupilumab) in …
President of Sanofi France expects COVID-19 vaccine to be priced below ten Euros
September 7, 2020Sales and Marketing COVID-19, GSK, Sanofi
The President of Sanofi France expects the coronavirus vaccine it is developing with GlaxoSmithKline to be priced under 10 Euros. …
Sanofi halts Phase 3 trial of Kevzara as a COVID-19 treatment
September 1, 2020Manufacturing and Production COVID-19, Sanofi, Vaccine, pharma
Sanofi is halting clinical trials treating serious COVID-19 patients with its Kevzara drug after data on its efficacy proved inconclusive.The …
Sanofi to buy Principia Biopharma for $3.4 billion
August 17, 2020Sales and Marketing MS, Sanofi
Sanofi is set to buy California based Principia Biopharma in a deal that is worth $3.4 billion. This deal means …
Sanofi indicted on manslaughter charges over its epilepsy drug Depakine
August 4, 2020Manufacturing and Production Sanofi, Vaccine
Sanofi is being investigated for manslaughter in France over the deaths of four babies whose mothers took its anti-epilepsy medication …
US Government commits $2.1bn to GSK and Sanofi’s COVID-19 vaccine candidate
July 31, 2020Medical Communications, Research and Development COVID-19, GSK, Sanofi, US, Vaccine
The US Government has announced additional funding into Sanofi and GlaxSmithKline’s efforts to develop a recombinant protein-based vaccine to the …
Sanofi’s nirsevimab nails study goals for prevention of respiratory syncytial virus in infants
July 30, 2020Research and Development Sanofi, nirsevimab, pharma
Sanofi’s nirsevimab met its goals in a Phase 2b study, the company has revealed, investigating its efficacy in the prevention …
UK Government secures 60 million doses of Sanofi and GSK’s COVID-19 vaccine
July 29, 2020Research and Development, Sales and Marketing COVID-19, GSK, Sanofi, UK government, pharma
The UK Government has sealed another deal to procure an effective COVID-19 vaccine for its citizens, partnering up with Sanofi …
Sanofi’s Dupixent scores Chinese approval in moderate to severe atopic dermatitis
June 22, 2020Sales and Marketing China, Dupixent, Sanofi, atopic dermatitis, pharma
China’s National Medical Products Administration (NMPA) has moved to approve a 300mg pre-filled pen formulation of Sanofi and Regeneron’s Dupixent …
Sanofi drops €610m on new vaccine research and manufacturing sites in France
June 16, 2020Manufacturing and Production COVID-19, Sanofi
The coronavirus outbreak has changed the way that the world prioritises healthcare resources, and lay bare just how unprepared many …
Mylan and Biocon’s Semglee, biosimilar to Sanofi’s Lantus, approved by FDA for type 1 and 2 diabetes
June 12, 2020Medical Communications, Sales and Marketing FDA, Lantus, Mylan Biocon, Sanofi, Semglee, diabetes
Mylan and Biocon have scored FDA approval with their insulin glargine injection Semglee, a biosimilar to Sanofi’s Lantus, in both …
